**MONOCLONAL ANTIBODY TO MOUSE C5**
close BB5.1

**Catalog no**
HM1073 (lot number and expiry date are indicated on the label)

**Description**
The monoclonal antibody BB5.1 binds the fifth component of mouse complement (C5). The complement system is a group of plasma and cell membrane proteins that play a key role in the immune system. All three pathways (classical, alternative & lectin) lead to the cleavage of C3 and eventually the formation of the cytolytic membrane attack complex C5b-9. If the activation cascade is allowed to proceed beyond the cleaving of C3 into C3a and C3b, an additional C3b molecule binds to the C3 convertases. This generates the C5 convertase (C3bBbC3b for the alternative pathway and C4bC2bC3b for the classical and lectin pathways). C5 convertase cleaves C5, releases the potent anaphylactic peptide C5a and generates C5b. C5b can initiate the terminal pathway, which recruits the components C6, C7, C8 and C9 to the surface of the target and inserts the C9 complex as a pore (termed the terminal complement complex) into the membrane. C5a is the most potent anaphylatoxin and a powerful chemotaxin for neutrophils and monocytes, with the ability to promote margination, extravasation, and activation of these cells. Thus, blocking C5 may be required for optimal inhibition of the inflammatory response. At the same time, inhibition of the complement cascade at C5 does not impair the generation of C3b through the classical and alternative pathways, preserving C3b-mediated opsonization of pathogenic microorganisms as well as opsonization and solubilization of immune complexes.

C5 is synthesized in the liver as a single polypeptide chain and is present in serum in a concentration of 50-80 µg/ml. Before secretion the molecule is glycosylated and secreted into plasma as a 190 kDa glycoprotein consisting of a disulphide linked alpha-chain (111 kDa) and beta-chain (75 kDa). Monoclonal antibody BB5.1 has been shown to precipitate the two chains of C5 from normal mouse serum and inhibited C5-dependent hemolysis in a functional complement test. Furthermore, BB5.1 administration completely inhibits terminal complement activity in murine models for antibody-mediated rejection (AMR) during heart and kidney transplantation. In another mouse model, both pretreatment as well as intervention with monoclonal antibody BB5.1 attenuates disease development during anti-MPO IgG-induced glomerulonephritis. Blockage of C5 activation by BB5.1 protects against renal ischemia-reperfusion injury by inhibition of late apoptosis and inflammation. In Lupus disease, combination therapy of anti-IL-10/anti-C5 (BB5.1) can both prevent and reduce the effect of the humoral immune response.

**Aliases**
Complement C5

**Immunogen**
Purified C5

**Species**
Mouse IgG1

**Cross reactivity**

<table>
<thead>
<tr>
<th>Cross reactant</th>
<th>Reactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**Formulation**
1 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin.

**Application**

<table>
<thead>
<tr>
<th></th>
<th>F³</th>
<th>FC</th>
<th>FS₂,₄,₅,₇</th>
<th>IA¹,₆</th>
<th>IF</th>
<th>IP¹</th>
<th>p⁴</th>
<th>W</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>●</td>
<td>●</td>
<td>N.D.</td>
<td></td>
<td>●</td>
<td></td>
<td>●</td>
<td></td>
</tr>
<tr>
<td>N.D.</td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td>●</td>
<td></td>
</tr>
</tbody>
</table>

N.D. = Not Determined; F = Frozen sections; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IF = Immuno Precipitation Fluorescence; IP = Immuno; P = Paraffin sections; W = Western blot
Application notes

FS: ex vivo: 50µg mAb/ml serum; in vivo: BALB/c mice 40mg mAb/kg/day, 0-2 days followed by twice a week.

IA: Wells were coated with 2-4µg purified BB5.1 in PBS as coat antibody for use in ELISA. IP: Mouse serum was pre-adsorbed with mouse-Ig affinity gel and prot-A-sepharose for 30' at RT. Then C5 was precipitated with BB5.1 (10µg mAb/ml followed by prot-A sepharose for 1h. Precipitated samples were analysed on 7% SDS/PAGE.

References

1. Frei, Y et al; Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol Cell Probes 1987, 1: 141

Use

For immunohistochemistry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user’s experimental setting.

Storage and stability

Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

Precautions

For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.

Also available

HM1045 Monoclonal antibody against Mouse C3, clone 11H9
HM1046 Monoclonal antibody against Mouse C4, clone 16D2
HM1051 Monoclonal antibody against Mouse Myeloperoxidase, clone 8F4
HM1096 Monoclonal antibody against Mouse C1q, clone JL-1
HP8013 Polyclonal antibody against Mouse C5